Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
D 19.49 -1.96% -0.39
RDUS closed down 1.96 percent on Friday, April 9, 2021, on 64 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical RDUS trend table...

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bearish Other -1.96%
Oversold Stochastic Weakness -1.96%
Oversold Stochastic Weakness -3.08%
50 DMA Resistance Bearish -5.39%
MACD Bearish Centerline Cross Bearish -5.39%
Inside Day Range Contraction -5.39%
Older End-of-Day Signals for RDUS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Radius Health, Inc. Description

Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biopharmaceutical Cancer Clinical Development Drugs Breast Cancer Treatment Of Breast Cancer Symptoms Thyroid Endocrine System Hormones Amines Osteoporosis Weight Loss Estrogen Metastases Cachexia Antiestrogens Estrogen Receptor Androgen Receptor Parathyroid Hormone Brain Metastases C Peptide Eisai Selective Estrogen Receptor Modulators

Is RDUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.1599
52 Week Low 10.1511
Average Volume 456,116
200-Day Moving Average 16.14
50-Day Moving Average 20.90
20-Day Moving Average 21.88
10-Day Moving Average 20.45
Average True Range 1.19
ADX 16.42
+DI 19.36
-DI 27.70
Chandelier Exit (Long, 3 ATRs ) 22.60
Chandelier Exit (Short, 3 ATRs ) 23.00
Upper Bollinger Band 25.29
Lower Bollinger Band 18.47
Percent B (%b) 0.15
BandWidth 31.15
MACD Line -0.35
MACD Signal Line 0.02
MACD Histogram -0.3718
Fundamentals Value
Market Cap 907.21 Million
Num Shares 46.5 Million
EPS -3.70
Price-to-Earnings (P/E) Ratio -5.27
Price-to-Sales 3.23
Price-to-Book 0.00
PEG Ratio -0.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.53
Resistance 3 (R3) 20.62 20.38 20.35
Resistance 2 (R2) 20.38 20.11 20.33 20.29
Resistance 1 (R1) 19.93 19.95 19.81 19.84 20.24
Pivot Point 19.69 19.69 19.63 19.64 19.69
Support 1 (S1) 19.24 19.42 19.12 19.15 18.74
Support 2 (S2) 19.00 19.26 18.95 18.69
Support 3 (S3) 18.55 19.00 18.63
Support 4 (S4) 18.46